https://www.socictopen.socict.org/files/original/37df98d4da19da89a50835fe9b3db8a3.pdf 3391d396913e803e4f1cba79f46a58e5 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Potential Antiviral Options against SARS-CoV-2 Infection Creator An entity primarily responsible for making the resource Aleksandr Ianevski, Magnar Bjoras, Denis E. Kainov, Eva Zusinaite, Tanel Tenson, Valentyn Oksenych, Hilde Lysvand, Rouan Yao, Mona Høysæter Fenstad, Svetlana Biza, Tuuli Reisberg, Kirsti Løseth, Veslemøy Malm Landsem, Janne Fossum Malmring, Sten Even Erlandsen, Per Arne Aas, Lars Hagen, Caroline H. Pettersen, Jan Egil Afset, Svein Arne Nordbø Description An account of the resource As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource antivirals, broad-spectrum antivirals, antiviral drug combinations Identifier An unambiguous reference to the resource within a given context 10.3390/v12060642 Source A related resource from which the described resource is derived Epidemiology and Health Publisher An entity responsible for making the resource available Korean Society of Epidemiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Microbiology